BioDiem options eye treatment peptide
02 October, 2003 by Tanya HollisMelbourne pharmaceutical development company BioDiem has taken an option over research involving the use of a peptide to treat major retinal diseases and age-related blindness.
Monsanto opens Qld research centre
01 October, 2003 by Melissa TrudingerMonsanto has opened a biotechnology research centre in Queensland to support its cotton product stewardship program.
VRI Biomedical completes Progastrim study
01 October, 2003 by Melissa TrudingerVRI Biomedical has completed a preliminary study demonstrating that their probiotic product Progastrim, which contains a proprietary strain of Lactobacillus fermentum, reduced respiratory symptoms in elite athletes.
Researchers call for FMD vaccine project
01 October, 2003 by Graeme O'NeillBritain's disastrous epidemic of foot and mouth disease (FMD) in 2001 cost the UK economy an estimated AUD$18 billion, and confirmed the what international veterinary authorities had feared: their insurance against the world's worst livestock disease had lapsed.
pSiMedica receives nod from US Patent Office
01 October, 2003 by Melissa TrudingerpSiMedica, the UK-based subsidiary of Perth nanotechnology company pSivida, has received a notice of allowance from the US Patent Office for "smart" drug delivery technology.
Metabolic adds pain compound to drug roster
01 October, 2003 by Graeme O'NeillMelbourne biotech Metabolic Pharmaceuticals (ASX:MBP) is looking for a fast and pain-free path to market for the latest addition to its IP portfolio: a potent peptide from cone-shell venom that shows great promise in the treatment of chronic, intractable nerve pain.
Cochlear JV making new noise in hearing technology
30 September, 2003 by Melissa TrudingerBionic ear pioneer Cochlear has formed a joint venture, Cochlear Acoustics, with Swiss hearing aid company Phonak Group to develop new technology combining implant technology with acoustic capabilities.
Cryptome Pharma files for IPO
29 September, 2003 by Iain ScottMelbourne-based Cryptome Pharmaceuticals has launched its first public share offer, filing a prospectus to list on the ASX in October.
BioGlobal in USDA deal
29 September, 2003 by Graeme O'NeillBrisbane 'green' agbiotech company BioGlobal has signed a cooperative R&D agreement with the US Department of Agriculture to develop its 'killer application' -- a cocktail of volatile floral compounds to lure noctuid moth pests to a lethal rendezvous
Tech tweak boosts Imugene
26 September, 2003 by Melissa TrudingerA change of promoter has given Imugene's (ASX:IMU) pig and poultry vaccine delivery systems a major boost, the company announced today.
Novogen subsidiary aims to float on Nasdaq
26 September, 2003 by Melissa TrudingerAustralian drug developer Novogen's US subsidiary Marshall Edwards has announced plans to float on the Nasdaq exchange, the company said today, with the prospect of raising up to $US13 million before costs associated with the float.
Celentis swims as PPL sinks
26 September, 2003 by Graeme O'NeillThe collapse of Scottish biotech PPL Therapeutics, of 'Dolly' fame, will force the company to sell off its New Zealand 'biopharm' at south Waikato and its 3000 transgenic sheep.
Gradipore hires CEO after six-month search
25 September, 2003 by Melissa TrudingerSydney-based bioseparations specialist Gradipore (ASX:GDP) has named former investment banker Greg Pynt as its new CEO. Pynt, whose previous roles include being joint head of equity capital markets at Deutsche Bank as well as a stint at Intersuisse, replaced US-based Bob Lieb, who quit the CEO post in May.
Select Vaccines signs hep E deal with Genelabs
25 September, 2003 by Melissa TrudingerMelbourne-based Select Vaccines (ASX:SLT) has signed its first agreement, with Singapore diagnostics company Genelabs Diagnostics, to bring the recently formed company's hepatitis E rapid diagnostic test to market.
Peptech confident in J&J royalty dispute
25 September, 2003 by Melissa TrudingerPeptech (ASX:PTD) is confident of coming out on top in its dispute with Centocor and its parent company Johnson & Johnson, the company said today after announcing the initiation of formal arbitration proceedings against the US firms.
